Central nervous system (CNS) symptoms have been reported in clinical trials and case reports in patients receiving raltegravir. We investigated CNS symptoms in 453 HIV-infected patients. Of these 47 (10.4%) developed at least one drug-related CNS symptom. Predictors of CNS symptoms were concomitant therapy with tenofovir or with proton pump inhibitors that can increase raltegravir concentration. Thus, our data suggest a possible correlation between high raltegravir plasma concentrations and CNS symptoms, and therefore their monitoring in clinical practice.
Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study / Madeddu, G., Menzaghi, B., Ricci, E., Carenzi, L., Martinelli, C., Di Biagio, A., Parrut, i.G., Orofino, G., Mura, M.S.A., Bonfanti, P.f.t.C.I.S.A.I.G.. - In: AIDS. - ISSN 0269-9370. - 26:18(2012), pp. 2412-2415. [10.1097/QAD.0b013e32835aa141]
Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study
MADEDDU, Giordano;MURA, Maria Stella Anna;
2012-01-01
Abstract
Central nervous system (CNS) symptoms have been reported in clinical trials and case reports in patients receiving raltegravir. We investigated CNS symptoms in 453 HIV-infected patients. Of these 47 (10.4%) developed at least one drug-related CNS symptom. Predictors of CNS symptoms were concomitant therapy with tenofovir or with proton pump inhibitors that can increase raltegravir concentration. Thus, our data suggest a possible correlation between high raltegravir plasma concentrations and CNS symptoms, and therefore their monitoring in clinical practice.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
